JaneWinterMD

PubMed

• A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
  Karmali, R., Reem Karmali, Carlos Galvez, Mehdi Hamadani, Leo Gordon, Jane Winter, Shuo Ma, Valerie Nelson, Timothy S Fenske, Nirav N Shah, Deepa Jagadeesh, Andreas Kl...> ;Blood Advances. 2024 Apr 9
• Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
  Hill, B., Ma, S., Zent, C., Baran, A., Wallace, D., Advani, A., Winter, A., Winter, J., Gordan, L., Karmali, R., Liesveld, J., Mulford, D., Rowland, C., Bui, A., Sport...> ;Blood Advances. 2024 Jan 23
• 2 citations
  Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma.
  Reem Karmali, Jeremy S Abramson, Shuo Ma, Juehua Gao, Adam M Petrich, Deborah M Stephens, Jeffrey Barnes, Jane N Winter, Jason Kaplan, Ephraim Hochberg, Tak Takvorian,...> ;Blood Advances. 2023 Dec 12
• Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
  Narendranath Epperla, Lei Feng, Nirav N Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M Stephens, Catherine J Lee, Thomas Ollila, Geoffrey Shouse, Alexey V Danilov, Ke...> ;Journal of Hematology & Oncology. 2023 Nov 9
• 4 citations
  Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
  Jia Ruan, Jasmine Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N Winter, Leo I Gordon, Reem Karmali, Jonathan Moreira, Adam M Petrich, Barbara Pro> ;Blood Advances. 2023 Oct 10
• 9 citations
  Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
  Joanna Zurko, Imran Nizamuddin, Narendranath Epperla, Kevin David, Jonathon B Cohen, Tamara K Moyo, Thomas Ollila, Brian Hess, Ishan Roy, Robert Ferdman, Jieqi Liu, Sa...> ;Blood Advances. 2023 Jun 27
• Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.
  Danielle S Wallace, Chris Rowland, Brian T Hill, Andrea M Baran, Carla Casulo, Patrick M Reagan, Allison Winter, Reem Karmali, Jane N Winter, Leo I Gordon, Andrew Bui,...> ;Leukemia & Lymphoma. 2023 Sep 1
• Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study.
  Peter G Doukas, Frederique St Pierre, Reem Karmali, Xinlei Mi, Jennifer Boyer, Mariana Nieves, Michael G Ison, Jane N Winter, Leo I Gordon, Shuo Ma> ;The Oncologist. 2023 Oct 3
• 9 citations
  Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investiga...
  Locke J Bryan, Carla Casulo, Pamela B Allen, Scott E Smith, Hatice Savas, Gary L Dillehay, Reem Karmali, Barbara Pro, Kaitlyn L Kane, Latifa A Bazzi, Joan S Chmiel, Br...> ;JAMA Oncology. 2023 May 1
• 1 citations
  Phase I study of novel SYK inhibitor TAK-659 (mivavotinib) in combination with R-CHOP for front-line treatment of high-risk diffuse large B-cell lymphoma.
  Reem Karmali, Frederique St-Pierre, Shuo Ma, Kelly D Foster, Jason Kaplan, Xinlei Mi, Barbara Pro, Jane N Winter, Leo I Gordon> ;Ejhaem. 2023 Feb 1
• Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
  Shuo Ma, Steven T Rosen, Maria Winqvist, Olga Frankfurt, Jane N Winter, Leo Gordon, Irene Helenowski, Hui Zhang, Jennifer Kreutzer, Sonja Sönnert-Husa, Anders Österbor...> ;Leukemia Research. 2022 Nov 1
• 2 citations
  Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area.
  Alain Mina, Carlos Galvez, Reem Karmali, Mary Mulcahy, Xinlei Mi, Masha Kocherginsky, Michael J Gurley, Neelima Katam, William Gradishar, Jessica K Altman, Michael G I...> ;Cancers. 2022 Apr 28
• 4 citations
  Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
  Ishan Roy, Gordon Smilnak, Madelyn Burkart, Elizabeth Hamilton, Katherine Thorp, Sarah Miyata, Shuo Ma, Barbara Pro, Jane Winter, Leo Gordon, Reem Karmali> ;British Journal of Haematology. 2022 Apr 1
• 14 citations
  Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
  Zijun Y Xu-Monette, Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Way...> ;Clinical Cancer Research. 2022 Mar 1
• 8 citations
  Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms.
  Maher Albitar, Hong Zhang, Andre Goy, Zijun Y Xu-Monette, Govind Bhagat, Carlo Visco, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Karen Dybkaer, April Chiu, Wayne Tam...> ;Blood Cancer Journal. 2022 Feb 1
• 12 citations
  A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas.
  William Pearse, Adam M. Petrich, Leo I. Gordon, Reem Karmali, Jane N. Winter, Shuo Ma, Jason B. Kaplan, Amir Behdad, Andreas K. Klein, Borko Jovanovic, Irene Helenowsk...> ;Leukemia & Lymphoma. 2021 Aug 2
• 4 citations
  Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
  Hua You, Zijun Y. Xu-Monette, Li Wei, Harry Nunns, Mate Nagy, Govind Bhagat, Xiaosheng Fang, Feng Zhu, C. Visco, A. Tzankov, Karen Dybkaer, April Chiu, Wayne Tam, Youl...> ;Oncoimmunology. 2021 Jan 1
• 17 citations
  Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
  Manman Deng, Zijun Y. Xu-Monette, Lan V. Pham, Xudong Wang, Alexandar Tzankov, Xiaosheng Fang, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkær, April Chiu, Wayne Ta...> ;Molecular Cancer Research. 2021 Feb 1
• 24 citations
  XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
  Manman Deng, Mingzhi Zhang, Zijun Y. Xu-Monette, Lan V. Pham, Alexandar Tzankov, Carlo Visco, Xiaosheng Fang, Govind Bhagat, Feng Zhu, Karen Dybkær, April Chiu, Wayne ...> ;Journal of Hematology & Oncology. 2020 Nov 4
• 75 citations
  Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
  Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Alan Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert Bayer...> ;Blood. 2021 Mar 11
• 13 citations
  A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
  Zijun Y. Xu-Monette, Hongwei Zhang, Feng Zhu, Alexandar Tzankov, Govind Bhagat, Carlo Visco, Karen Dybkær, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Hua You, Joory...> ;Blood Advances. 2020 Jul 28
• 84 citations
  Hodgkin lymphoma, version 2.2020
  Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M Boughan, Bout...> ;Journal of the National Comprehensive Cancer Network. 2020 Jun 1
• 12 citations
  A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
  Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Sin...> ;Clinical Cancer Research. 2020 Jan 1
• 16 citations
  Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
  Zijun Y. Xu-Monette, Jianyong Li, Yi Xia, Beryl Crossley, Robert D. Bremel, Yi Miao, Min Xiao, Thomas M. Snyder, Ganiraju C. Manyam, Xiaohong Tan, Hongwei Zhang, Carlo...> ;Journal for Immunotherapy of Cancer. 2019 Oct 22
• 89 citations
  Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.
  Timothy A. Yap, Jane N. Winter, Lisa Giulino-Roth, Jemma Longley, Juanita Lopez, Jean-Marie Michot, John P. Leonard, Vincent Ribrag, Michael T. McCabe, Caretha L. Crea...> ;Clinical Cancer Research. 2019 Aug 30
• Join now to see all

Abstracts/Posters

• Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Mul...
  Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classi...
  Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
  Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
  Jane N. Winter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A Phase II Studyof Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monot... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018